Comparative prognostic value of cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma

被引:0
作者
Gohring, UJ [1 ]
Scharl, A [1 ]
Thelen, U [1 ]
Ahr, A [1 ]
Crombach, G [1 ]
机构
[1] UNIV DUSSELDORF,DEPT OBSTET & GYNAECOL,W-4000 DUSSELDORF,GERMANY
关键词
breast cancer; immunohistochemistry; cathepsin D; urokinase plasminogen activator(uPA); prognosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The lysosomal protease Cathepsin D and the serine protease urokinase plasminogen activator (uPA) are suspected to indicate poor prognosis in primary breast carcinoma. We tested Cathepsin D and uPA immunohistochemically in 281 surgical specimens of primary ductal infiltrating breast carcinomas. Staining was evaluated, taking intracytoplasmic immunoreactions into account, in tumour cells and tumour infiltrating macrophages. Positivity was established in 48.4% and 58.0% of tissue samples for cathepsin D and uPA respectively (co-expression: 67.6%). In patients with cathepsin D- or uPA-positive tumours, relapses were more frequent and disease-free survival was shorter irrespective of nodal status, receptor status or menopausal status, (median observation time 74 months). However, this trend was statistically significant only for cathepsin D. With stepwise cox regression analysis, borderline significance (p = 0.07) was calculated for cathepsin D only in node-negative was patients. The combination of cathepsin D with uPA measurements did nor enhance its prognostic value. Immunohistochemical detection of Cathepsin D could potentially be used to identify patients with poor prognosis in the group of node negative breast cancer patients.
引用
收藏
页码:1011 / 1018
页数:8
相关论文
共 45 条
[31]   THE ORIGIN AND FUNCTION OF TUMOR-ASSOCIATED MACROPHAGES [J].
MANTOVANI, A ;
BOTTAZZI, B ;
COLOTTA, F ;
SOZZANI, S ;
RUCO, L .
IMMUNOLOGY TODAY, 1992, 13 (07) :265-270
[32]  
Marc M., 1990, MOL ENDOCRINOL, V4, P1327
[33]   HOW TO USE PROGNOSTIC FACTORS IN AXILLARY NODE-NEGATIVE BREAST-CANCER PATIENTS [J].
MCGUIRE, WL ;
TANDON, AK ;
ALLRED, DC ;
CHAMNESS, GC ;
CLARK, GM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) :1006-1015
[34]   DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT .2. ANALYSIS AND EXAMPLES [J].
PETO, R ;
PIKE, MC ;
ARMITAGE, P ;
BRESLOW, NE ;
COX, DR ;
HOWARD, SV ;
MANTEL, N ;
MCPHERSON, K ;
PETO, J ;
SMITH, PG .
BRITISH JOURNAL OF CANCER, 1977, 35 (01) :1-39
[35]  
PYKE C, 1993, CANCER RES, V53, P1911
[36]   CATHEPSIN-D BY WESTERN BLOTTING AND IMMUNOHISTOCHEMISTRY - FAILURE TO CONFIRM CORRELATIONS WITH PROGNOSIS IN NODE-NEGATIVE BREAST-CANCER [J].
RAVDIN, PM ;
TANDON, AK ;
ALLRED, DC ;
CLARK, GM ;
FUQUA, SAW ;
HILSENBECK, SH ;
CHAMNESS, GC ;
OSBORNE, CK .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :467-474
[37]   CATHEPSIN D IN BREAST-CANCER - A TISSUE MARKER ASSOCIATED WITH METASTASIS [J].
ROCHEFORT, H .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) :1780-1783
[38]  
ROSNER D, 1991, CANCER, V68, P1482, DOI 10.1002/1097-0142(19911001)68:7<1482::AID-CNCR2820680704>3.0.CO
[39]  
2-J
[40]   STEROID-RECEPTORS, PS2 AND CATHEPSIN-D IN EARLY CLINICALLY NODE-NEGATIVE BREAST-CANCER [J].
STONELAKE, PS ;
BAKER, PG ;
GILLESPIE, WM ;
DUNN, JA ;
SPOONER, D ;
MORRISON, JM ;
BUNDRED, NJ ;
OATES, GD ;
LEE, MJR ;
NEOPTOLEMOS, JP ;
CHAN, SY ;
BAKER, PR .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (01) :5-11